Journal List > Korean Circ J > v.20(1) > 1072548

TOOLS
Yoo, Koh, Cho, and Choi: Effect of Pravastatin on Serum Lipids of Patient with Primary Hyperlipidemia
Original Article
Korean Circulation Journal

Korean Circulation Journal 1990; 20(1): 128-134.

Published online: 31 March 1990

DOI: https://doi.org/10.4070/kcj.1990.20.1.128

Effect of Pravastatin on Serum Lipids of Patient with Primary Hyperlipidemia

Won-sang Yoo, M.D., Won-Sub Koh, M.D., Byoung-Yul Cho, M.D., Suck-Koo Choi, M.D.

Copyright © 1990 The Korean Society of Circulation

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A new hypolipidemic drug, pravastatin, hydroxymethylglutaryl coenzyme A reductase inhibitor was administered to 33 patients with primary hyperlipidemia, 10mg daily for 8 weeks and sequential changes of lipid profile were analysed as follows.
1) Mean value at baseline period of total cholesterol, triglyceride, high and low density lipoprotein cholesterol were 260, 220, 51 and 163mg/dl respectively.
2) Total cholesterol showed 21% decrease at the end of 8 weeks and that of LDL-cholesterol were 30%.
3) Triglyceride decreased 16% at the end of 8 weeks and increment of HDL-cholesterol was 8% at the end of 8 weeks.
4) No serious side reactions were observed except one patient, who showed generalized skin rash which last 3 days and did not prevent further medication.
In conclusion, pravastatin is a safe and useful hypolipidemic agent for the patient with primary hyperlipidemia.

Keywords: Pravastatin, HMG CoA reductase inhibitor, Hyperlipidemia

TOOLS
Similar articles